Literature DB >> 1176584

Effect of spironolactone on sex hormones in man.

B Stripp, A A Taylor, F C Bartter, J R Gillette, D L Loriaux, R Easley, R H Menard.   

Abstract

Administration spironolactone at a dosage of 400 mg/day to healthy male volunteers for 5 days resulted in a significant rise in plasma progesterone and 17alpha-hydroxyprogesterone which persisted throughout the study. A transient increase in plasma FSH and LH concentration was observed after the second but not the third or fifth days of drug administration. There was no change in plasma concentration of testosterone, 17beta-estradiol, or prolactin. These findings are consistent with a previously-reported spironolactone-induced destruction of the microsomal enzyme cytochrome P-450, an enzyme necessary for 17-hydroxylase and desmolase activity. The results do not explain the decrease of libido, the impotence, and the gynecomastia frequently associated with spironolactone therapy in males.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1176584     DOI: 10.1210/jcem-41-4-777

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  Effect of spironolactone on acid and alkaline phosphatase in the testes of albino rat.

Authors:  P K Singh; D P Singh
Journal:  Indian J Clin Biochem       Date:  2005-01

2.  Testotoxicosis: gonadotrophin-independent male sexual precocity.

Authors:  A A Aziz; S M Jafri; N U Haque
Journal:  Postgrad Med J       Date:  1992-03       Impact factor: 2.401

Review 3.  Hirsutism and the effectiveness of spironolactone in its management.

Authors:  G R McMullen; A J Van Herle
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

4.  Interference of spironolactone therapy with adrenal steroid metabolism in secondary hyperaldosteronism.

Authors:  U Abshagen; S Spörl; M Schöneshöfer; M L'age; W Oelkers
Journal:  Klin Wochenschr       Date:  1978-04-01

5.  Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.

Authors:  P Ye; T Yamashita; D M Pollock; H Sasano; W E Rainey
Journal:  Horm Metab Res       Date:  2008-09-25       Impact factor: 2.936

6.  Familial testotoxicosis in a Chinese family.

Authors:  Y J Lim; L C Low
Journal:  Eur J Pediatr       Date:  1994-04       Impact factor: 3.183

7.  Lack of endocrine systemic side effects after topical application of spironolactone in man.

Authors:  F O Rey; C Valterio; L Locatelli; A A Ramelet; J P Felber
Journal:  J Endocrinol Invest       Date:  1988-04       Impact factor: 4.256

8.  Progesterone, prolactin, and gynaecomastia in men with liver disease.

Authors:  M J Farthing; J R Green; C R Edwards; A M Dawson
Journal:  Gut       Date:  1982-04       Impact factor: 23.059

9.  Polycystic ovarian disease: endocrinological parameters with specific reference to growth hormone and somatomedin-C.

Authors:  W Urdl
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

10.  Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism.

Authors:  M Messina; C Manieri; P Biffignandi; C Massucchetti; R F Novi; G M Molinatti
Journal:  J Endocrinol Invest       Date:  1983-02       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.